Specifically, given that COVID-19 infection has been associated with liver enzyme abnormalities [42,43], elevated plasma levels of IL-6 [44], and increased risks for kidney injury and renal failure [45], LpX and/or LpZ particles may constitute key prognostic biomarkers in such patients. This evidence concerns the gene IL6 and kidney failure.